Literature DB >> 26415692

Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study.

Dina Popovic1, Eduard Vieta1, Jean-Michel Azorin2, Jules Angst3, Charles L Bowden4, Sergey Mosolov5, Allan H Young6, Giulio Perugi7.   

Abstract

OBJECTIVES: The Bipolar Disorders: Improving Diagnosis, Guidance, and Education (BRIDGE-II-Mix) study aimed to estimate the frequency of mixed states in patients with a major depressive episode (MDE) according to different definitions and to compare their clinical validity, looking into specific features such as suicidality.
METHODS: A total of 2,811 subjects were enrolled in this multicenter cross-sectional study. Psychiatric symptoms, and sociodemographic and clinical variables were collected. The analysis compared the characteristics of patients with MDE with (MDE-SA group) and without (MDE-NSA) a history of suicide attempts.
RESULTS: The history of suicide attempts was registered in 628 patients (22.34%). In the MDE-SA group, women (72.5%, p = 0.028), (hypo)mania in first-degree relatives (20.5%, p < 0.0001), psychotic features (15.1%, p < 0.0001), and atypical features (9.2%, p = 0.009) were more prevalent. MDE-SA patients' previous responses to treatment with antidepressants included more (hypo)manic switches [odds ratio (OR) = 1.97, 95% confidence interval (CI): 1.58-2.44, p < 0.0001], treatment resistance (OR = 2.07, 95% CI: 1.72-2.49, p < 0.0001), mood lability (OR = 1.98, 95% CI: 1.65-2.39, p < 0.0001), and irritability (OR = 1.80, 95% CI: 1.48-2.17, p < 0.0001). Multivariate analysis evidenced that risky behavior, psychomotor agitation and impulsivity, and borderline personality and substance use disorders were the variables most frequently associated with previous suicide attempts. In the MDE-SA group, 75 patients (11.9%) fulfilled Diagnostic and Statistical Manual (DSM)-5 criteria for MDE with mixed features, and 250 patients (39.8%) fulfilled research-based diagnostic criteria for a mixed depressive episode.
CONCLUSIONS: Important differences between MDE-SA and MDE-NSA patients have emerged. Early identification of symptoms such as risky behavior, psychomotor agitation, and impulsivity in patients with MDE, and treatment of mixed depressive states could represent a major step in suicide prevention.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar disorder; mixed features; suicide attempts

Mesh:

Substances:

Year:  2015        PMID: 26415692     DOI: 10.1111/bdi.12338

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  14 in total

1.  The necessity, validity, and clinical utility of a new diagnostic entity: Acute suicidal affective disturbance.

Authors:  Megan L Rogers; Carol Chu; Thomas Joiner
Journal:  J Clin Psychol       Date:  2019-01-11

Review 2.  Rethinking the spectrum of mood disorders: implications for diagnosis and management - Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France.

Authors:  Roger S McIntyre; Allan H Young; Peter M Haddad
Journal:  Ther Adv Psychopharmacol       Date:  2018-03-25

3.  Sex Differences in Bipolar Disorders: Impact on Psychopathological Features and Treatment Response.

Authors:  Giulia Menculini; Luca Steardo; Tiziana Sciarma; Martina D'Angelo; Laura Lanza; Gianmarco Cinesi; Federica Cirimbilli; Patrizia Moretti; Norma Verdolini; Pasquale De Fazio; Alfonso Tortorella
Journal:  Front Psychiatry       Date:  2022-06-10       Impact factor: 5.435

4.  Research on the Development of Theme Trends and Changes of Knowledge Structures of Drug Therapy Studies on Major Depressive Disorder Since the 21st Century: A Bibliometric Analysis.

Authors:  Li Duan; Yunfeng Gao; Xiaojun Shao; ChunSheng Tian; Chunfeng Fu; Gang Zhu
Journal:  Front Psychiatry       Date:  2020-07-10       Impact factor: 4.157

5.  Treatment of mixed depression with theta-burst stimulation (TBS): results from a double-blind, randomized, sham-controlled clinical trial.

Authors:  Diego Freitas Tavares; Paulo Suen; Carla Garcia Rodrigues Dos Santos; Doris Hupfeld Moreno; Leandro Da Costa Lane Valiengo; Izio Klein; Lucas Borrione; Pamela Marques Forte; André R Brunoni; Ricardo Alberto Moreno
Journal:  Neuropsychopharmacology       Date:  2021-06-30       Impact factor: 7.853

Review 6.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

7.  Potential metabolic monitoring indicators of suicide attempts in first episode and drug naive young patients with major depressive disorder: a cross-sectional study.

Authors:  Ke Zhao; Siyao Zhou; Xiang Shi; Jianjun Chen; Yaoyao Zhang; Kaili Fan; Xiangyang Zhang; Wei Wang; Wei Tang
Journal:  BMC Psychiatry       Date:  2020-07-28       Impact factor: 3.630

8.  Deconstructing major depressive episodes across unipolar and bipolar depression by severity and duration: a cross-diagnostic cluster analysis on a large, international, observational study.

Authors:  Filippo Corponi; Gerard Anmella; Isabella Pacchiarotti; Ludovic Samalin; Norma Verdolini; Dina Popovic; Jean-Michel Azorin; Jules Angst; Charles L Bowden; Sergey Mosolov; Allan H Young; Giulio Perugi; Eduard Vieta; Andrea Murru
Journal:  Transl Psychiatry       Date:  2020-07-19       Impact factor: 6.222

9.  Electroconvulsive Therapy (ECT) in Bipolar Disorder Patients with Ultra-Rapid Cycling and Unstable Mixed States.

Authors:  Sergey Mosolov; Christoph Born; Heinz Grunze
Journal:  Medicina (Kaunas)       Date:  2021-06-15       Impact factor: 2.430

10.  A new stress sensor and risk factor for suicide: the T allele of the functional genetic variant in the GABRA6 gene.

Authors:  Xenia Gonda; Jane Sarginson; Nora Eszlari; Peter Petschner; Zoltan G Toth; Daniel Baksa; Gabor Hullam; Ian M Anderson; J F William Deakin; Gabriella Juhasz; Gyorgy Bagdy
Journal:  Sci Rep       Date:  2017-10-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.